May 18, 2018 / 1:36 PM / 6 months ago

BRIEF-Abeona Therapeutics Provides Clinical Update On MPS IIIA Gene Therapy Trial

May 18 (Reuters) - Abeona Therapeutics Inc:

* ABEONA THERAPEUTICS PROVIDES CLINICAL UPDATE ON MPS IIIA GENE THERAPY TRIAL AT THE 21ST ANNUAL ASGCT MEETING

* ABEONA THERAPEUTICS- ABO-102 18-MONTH EFFICACY & SAFETY DATA CONTINUE TO DEMONSTRATE TIME- & DOSE-DEPENDENT REDUCTIONS IN UNDERLYING DISEASE PATHOLOGY

* ABEONA THERAPEUTICS- RESULTS FROM PHASE 1/2 CLINICAL TRIAL FOR ABO-102 SHOW DURABLE BIOPHYSICAL REDUCTIONS OF DISEASE BURDEN

* ABEONA THERAPEUTICS INC - ABO-102 IS WELL-TOLERATED IN ALL SUBJECTS TO DATE, WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS REPORTED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below